MAPT and Alzheimer disease: The donanemab findings in lateral temporal regions converges with our findings in IT tau, and although we did not find consistent accumulation across frontal regions, this discrepancy could be related to differences in cohort characteristics (e.g., our study is focused on CU and MCI, whereas the donanemab trial was focused on early symptomatic AD (Mintun et al., 2021)).